TGA ticks booming drug

Posted 16 April 2025 AM

UCB's Bimzelx has landed another approval from the TGA, just before the PBAC considers a submission for funding at its May meeting.

Bimzelx is now approved for the treatment of adults living with moderate to severe hidradenitis suppurativa (HS) with an inadequate response to conventional systemic HS therapy. It's the first treatment for the disease that selectively inhibits interleukin 17F (IL-17F) and interleukin 17A (IL-17A) cytokines.

To see the whole article, please login